Skin and Soft Tissue Infections

Identifying the cause of skin, surgical site, and wound infections is necessary to effectively prescribe treatment. With 50-percent methicillin resistance in S. aureus, the need for rapid diagnostics is becoming more imperative for ensuring better clinical outcomes.

Currently, no means exist to cost-effectively and rapidly identify the presence of methicillin-resistant S. aureus and methicillin-susceptible S. aureus in skin and soft tissue infections. MicroPhage intends to introduce the MicroPhage MRSA/MSSA Skin and Soft Tissue Infection Test that is designed to rapidly identify the presence of S. aureus and determine methicillin resistance (MRSA) and methicillin susceptibility (MSSA).

Using our easy-to-use bacteriophage amplification platform, the test will provide culture-quality results in hours without the need for expensive equipment, batching, or specialized personnel. By providing results days before traditional ID/AST results, the MicroPhage test will enable more effective treatment and improved patient care.

Get definitive results faster than standard diagnostic methods – Receive culture-quality results in hours, not days.
Benefit from an easy-to-use platform – Go direct from a sample – without the need for expensive equipment, batching, or specialized personnel.
Enable more effective treatments – Get critical identification and antibiotic susceptibility and resistance information to enable the most-appropriate treatment.
Improve outcomes – Reduce treatment delays, complications, and costs.
Simplify testing with a phenotypic test – Rely on viable bacteria for results that are directly related to the sample – no primers or molecular markers.

This test is not cleared by the U.S. FDA nor CE Marked and not yet available for sale.